Johnson & Johnson Bolsters US Operations and Delivers Reliable Returns

Healthcare conglomerate Johnson & Johnson is demonstrating its financial strength through a significant expansion of its US manufacturing footprint and its unwavering commitment to shareholder returns.

Unwavering Dividend Commitment

For income-focused investors, Johnson & Johnson remains a cornerstone holding. The company has just announced a dividend payment of $1.30 per share for the third quarter of 2025. This distribution marks an incredible 63 consecutive years of dividend increases, a record that highlights the firm’s exceptional and consistent ability to generate cash flow.

This reliability is not lost on major institutional players. Notably, Sector Gamma AS increased its stake in the company by 25.6% during the first quarter of 2025, elevating Johnson & Johnson to become its sixth-largest holding.

Major Manufacturing Investment in North Carolina

Supporting its long-term growth, Johnson & Johnson is making a substantial capital investment to scale its production capabilities. The company has committed $2 billion to establish a new manufacturing facility at the Fujifilm Diosynth site in Holly Springs, North Carolina.

Spanning more than 1.7 million square feet, the new operation is scheduled to become operational later this year. Over the next ten years, this project is expected to create approximately 120 new jobs. This initiative is a key component of a larger, $55 billion multi-faceted plan to bolster US production, research, and technology investments over the coming four years. This represents a 25% increase compared to the previous four-year period.

Should investors sell immediately? Or is it worth buying Johnson & Johnson?

Robust Performance and Upgraded Forecasts

The company’s Innovative Medicine division continues to be a powerful growth engine, even amid competitive pressures from biosimilars for products like Stelara. The division’s second-quarter 2025 performance was strong, posting global operational sales growth of 5.8% to reach $23.7 billion.

Buoyed by these results, management has raised its full-year 2025 guidance. The company now anticipates sales between $93.2 billion and $93.6 billion, with adjusted earnings per share projected in the range of $10.80 to $10.90. The oncology portfolio is showing particular vigor, with prostate cancer treatment Erleada generating $908 million in sales—a 17.8% jump from the prior quarter.

This commercial success is fueled by a deep commitment to research and development. In 2024 alone, the company invested $17.44 billion in R&D.

Market Analysts Favor Further Appreciation

The market is responding positively to this strategic direction. On August 21, analysts at Citigroup reaffirmed their “Buy” rating on the stock while lifting their price target from $185 to $200. This optimistic sentiment is echoed by various AI-driven forecasting models, which continue to signal a positive outlook and suggest the stock possesses excellent upside potential.

Johnson & Johnson’s shares closed on August 22 with a 0.20 percent gain. The company’s aggressive manufacturing expansion and consistent financial performance appear to be reinforcing its trajectory as a healthcare industry leader.